Roche Enters Hearing-Loss Space In Risk-Sharing Venture With Inception, Versant

The newly formed Inception 3 will work to bring small molecule candidates for hearing loss, based on technology licensed from Stanford University, to IND-filing stage, at which point Roche will have the option to buy out the program.